Shore Capital reiterated their hold rating on shares of AstraZeneca plc (LON:AZN) in a report issued on Wednesday morning, StockTargetPrices.com reports.
Other analysts have also issued research reports about the stock. Deutsche Bank AG reiterated a buy rating and issued a GBX 5,500 ($69.96) target price on shares of AstraZeneca plc in a research report on Wednesday, March 15th. Jefferies Group LLC lifted their target price on shares of AstraZeneca plc from GBX 5,250 ($66.78) to GBX 5,350 ($68.05) and gave the company a buy rating in a research report on Thursday, March 9th. Liberum Capital restated a buy rating and set a GBX 5,100 ($64.87) price target on shares of AstraZeneca plc in a research report on Thursday, March 9th. Bryan, Garnier & Co restated a buy rating and set a GBX 5,400 ($68.68) price target on shares of AstraZeneca plc in a research report on Tuesday, February 28th. Finally, Berenberg Bank lowered their price target on shares of AstraZeneca plc from GBX 5,500 ($69.96) to GBX 5,450 ($69.32) and set a buy rating on the stock in a research report on Tuesday, February 21st. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of GBX 5,251.89 ($66.80).
Shares of AstraZeneca plc (AZN) opened at 5429.00 on Wednesday. The stock’s market cap is GBX 68.72 billion. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,519.00. The firm’s 50-day moving average price is GBX 5,134.14 and its 200-day moving average price is GBX 4,718.55.
TRADEMARK VIOLATION WARNING: This article was first reported by sleekmoney and is the property of of sleekmoney. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://sleekmoney.com/astrazeneca-plc-azn-receives-hold-rating-from-shore-capital-2/1941938.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/astrazeneca-plc-azn-receives-hold-rating-from-shore-capital-2/1941938.html
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.